WO1994021295B1 - Procedes pour inhiber les maladies associees au vih au moyen d'anticorps monoclonaux diriges contre les lymphocytes t cytotoxiques anti-self - Google Patents
Procedes pour inhiber les maladies associees au vih au moyen d'anticorps monoclonaux diriges contre les lymphocytes t cytotoxiques anti-selfInfo
- Publication number
- WO1994021295B1 WO1994021295B1 PCT/US1994/003055 US9403055W WO9421295B1 WO 1994021295 B1 WO1994021295 B1 WO 1994021295B1 US 9403055 W US9403055 W US 9403055W WO 9421295 B1 WO9421295 B1 WO 9421295B1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- monoclonal antibodies
- cytotoxic
- directed against
- antibodies directed
- self
- Prior art date
Links
- 229960000070 antineoplastic Monoclonal antibodies Drugs 0.000 title claims abstract 6
- 229960000060 monoclonal antibodies Drugs 0.000 title claims abstract 6
- 102000005614 monoclonal antibodies Human genes 0.000 title claims abstract 6
- 108010045030 monoclonal antibodies Proteins 0.000 title claims abstract 6
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 title claims abstract 5
- 201000010099 disease Diseases 0.000 title abstract 3
- 230000002401 inhibitory effect Effects 0.000 title abstract 2
- 241000725303 Human immunodeficiency virus Species 0.000 claims abstract 5
- 210000000400 T-Lymphocytes, Cytotoxic Anatomy 0.000 claims abstract 4
- 239000000427 antigen Substances 0.000 claims abstract 4
- 102000038129 antigens Human genes 0.000 claims abstract 4
- 108091007172 antigens Proteins 0.000 claims abstract 4
- 238000001802 infusion Methods 0.000 claims abstract 2
- 230000002101 lytic Effects 0.000 claims 3
- 206010000565 Acquired immunodeficiency syndrome Diseases 0.000 claims 1
- 210000004369 Blood Anatomy 0.000 claims 1
- 102100001475 ITGB2 Human genes 0.000 claims 1
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 201000009910 diseases by infectious agent Diseases 0.000 abstract 1
- 230000001131 transforming Effects 0.000 abstract 1
Abstract
L'invention se rapporte à un procédé pour traiter et inhiber les maladies associées au virus de l'immunodéficience humaine (VIH). Ce procédé consiste à transformer l'infection par VIH en une maladie non grave par l'injection d'anticorps monoclonaux dirigés contre des antigènes particuliers sur des lymphocytes T cytotoxiques anti-CD4 'anti-self' (lymphocytes tuant les cellules saines du même organisme).
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU65221/94A AU684074B2 (en) | 1993-03-19 | 1994-03-21 | Methods for inhibiting HIV associated disease using monoclonal antibodies directed against anti-self cytotoxic T-cells |
| DE69433789T DE69433789T2 (de) | 1993-03-19 | 1994-03-21 | Methoden zur inhibition von hiv-assotiierte krankheit mittels monoklonaler antikörper gegen sich selbst gerichtete zytotoxische t-zellen |
| EP94912826A EP0690725B1 (fr) | 1993-03-19 | 1994-03-21 | Procedes pour inhiber la maladie associee au vih au moyen d'anticorps monoclonaux diriges contre les lymphocytes t cytotoxiques anti-self |
| AT94912826T ATE267019T1 (de) | 1993-03-19 | 1994-03-21 | Methoden zur inhibition von hiv-assotiierte krankheit mittels monoklonaler antikörper gegen sich selbstgerichtete zytotoxische t-zellen |
| CA002156495A CA2156495C (fr) | 1993-03-19 | 1994-03-21 | Methodes pour empecher l'apparition de maladies associees au vih, grace a des anticorps diriges contre les cellules t cytotoxiques anti-self |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3340593A | 1993-03-19 | 1993-03-19 | |
| US08/033,405 | 1993-03-19 | ||
| US16575193A | 1993-12-13 | 1993-12-13 | |
| US08/165,751 | 1993-12-13 | ||
| CA002425086A CA2425086A1 (fr) | 1993-03-19 | 2003-04-10 | Methode d'accroissement de la reaction d'hypersensibilite retardee par infusion d'anticorps specifiques de la lfa-1 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO1994021295A1 WO1994021295A1 (fr) | 1994-09-29 |
| WO1994021295B1 true WO1994021295B1 (fr) | 1994-10-27 |
Family
ID=34084057
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US1994/003055 WO1994021295A1 (fr) | 1993-03-19 | 1994-03-21 | Procedes pour inhiber les maladies associees au vih au moyen d'anticorps monoclonaux diriges contre les lymphocytes t cytotoxiques anti-self |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US5424066A (fr) |
| EP (2) | EP1438970B1 (fr) |
| AT (2) | ATE408418T1 (fr) |
| AU (1) | AU684074B2 (fr) |
| CA (2) | CA2156495C (fr) |
| DE (2) | DE69435142D1 (fr) |
| DK (1) | DK1438970T3 (fr) |
| ES (2) | ES2219647T3 (fr) |
| HK (1) | HK1067958A1 (fr) |
| PT (2) | PT690725E (fr) |
| WO (1) | WO1994021295A1 (fr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6534057B2 (en) | 1993-03-19 | 2003-03-18 | Allen D. Allen | Method increasing the delayed-type hypersensitivity response by infusing LFA-1-specific antibodies |
| US5651970A (en) * | 1993-03-19 | 1997-07-29 | Allen; Allen D. | Method for inhibiting disease associated with the human immunodeficiency virus through the use of monoclonal antibodies directed against anti-self cytotoxic T-lymphocytes or their lytics |
| AU2248395A (en) * | 1994-04-15 | 1995-11-10 | Allen D. Allen | Method of treating hiv infection using antibodies against cytotoxic t-cells and thymic humoral factor |
| CA2191333C (fr) * | 1995-04-14 | 2006-08-01 | Hirofumi Moriyama | Composition a phosphorescence persistante |
| WO1996039187A1 (fr) * | 1995-06-06 | 1996-12-12 | Allen D Allen | Procede de traitement de molluscum contagiosum suite a une infection par vih |
| AU6091696A (en) * | 1995-06-07 | 1996-12-30 | Connective Therapeutics Inc. | Treating immune deficiency diseases using t cell receptor pe ptides |
| WO1998037917A1 (fr) * | 1997-02-28 | 1998-09-03 | Enzo Therapeutics, Inc., A Fully Owned Subsidiary Of Enzo Biochem, Inc. | Nouveaux procedes de retro-regulation immunitaire selective (sidr) |
| US20030170258A1 (en) * | 2001-05-09 | 2003-09-11 | Enzo Therapeutics, Inc. | Novel processes implementing selective immune down regulation (SIDR) |
| US6919077B2 (en) * | 2002-09-27 | 2005-07-19 | Aids Research, Llc | LFA-1 alpha subunit antibodies and methods of use |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5002869A (en) * | 1987-11-02 | 1991-03-26 | Dana-Farber Cancer Institute | Monoclonal antibody specific to a novel epitope of the LFA-1 antigen of human T lymphocytes |
-
1994
- 1994-03-21 PT PT94912826T patent/PT690725E/pt unknown
- 1994-03-21 AT AT04101437T patent/ATE408418T1/de active
- 1994-03-21 AU AU65221/94A patent/AU684074B2/en not_active Ceased
- 1994-03-21 DE DE69435142T patent/DE69435142D1/de not_active Expired - Lifetime
- 1994-03-21 EP EP04101437A patent/EP1438970B1/fr not_active Expired - Lifetime
- 1994-03-21 ES ES94912826T patent/ES2219647T3/es not_active Expired - Lifetime
- 1994-03-21 DK DK04101437T patent/DK1438970T3/da active
- 1994-03-21 ES ES04101437T patent/ES2314341T3/es not_active Expired - Lifetime
- 1994-03-21 AT AT94912826T patent/ATE267019T1/de not_active IP Right Cessation
- 1994-03-21 DE DE69433789T patent/DE69433789T2/de not_active Expired - Lifetime
- 1994-03-21 EP EP94912826A patent/EP0690725B1/fr not_active Expired - Lifetime
- 1994-03-21 CA CA002156495A patent/CA2156495C/fr not_active Expired - Lifetime
- 1994-03-21 WO PCT/US1994/003055 patent/WO1994021295A1/fr active IP Right Grant
- 1994-03-21 PT PT04101437T patent/PT1438970E/pt unknown
- 1994-09-07 US US08/302,113 patent/US5424066A/en not_active Expired - Lifetime
-
2003
- 2003-04-10 CA CA002425086A patent/CA2425086A1/fr not_active Abandoned
-
2005
- 2005-01-08 HK HK05100178A patent/HK1067958A1/xx not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3383303B2 (ja) | ＣＤｗ５２−多発性硬化症の治療のための特異抗体 | |
| US6113901A (en) | Methods of stimulating or enhancing the immune system with anti-CD3 antibodies | |
| DE69130709T3 (de) | Gezielte immunostimulierung mit bispezifischen stoffen | |
| Fahey et al. | Status of immune‐based therapies in HIV infection and AIDS | |
| WO1994021295B1 (fr) | Procedes pour inhiber les maladies associees au vih au moyen d'anticorps monoclonaux diriges contre les lymphocytes t cytotoxiques anti-self | |
| Carter et al. | Infectiousness and gamete immunization in malaria | |
| HK1067958A1 (en) | Methods for inhibiting hiv associated disease using monoclonal antibodies directed against anti-selfcytotoxic t-cells | |
| EP0153969B1 (fr) | Composition pour le traitement de la peau à base de facteur transfert | |
| Nelson et al. | Macrophages and resistance to tumors. IV. Influence of age on susceptibility of mice to anti-inflammatory and antimacrophage effects of tumor cell products | |
| US5178858A (en) | Method for prevention of graft versus host disease | |
| EP0028815B1 (fr) | Utilisation de la ricine et d'une composition pharmaceutique la contenant pour augmenter la réponse immunologique | |
| Jabs | MSL-109 adjuvant therapy for cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome: the Monoclonal Antibody Cytomegalovirus Retinitis Trial | |
| US5651970A (en) | Method for inhibiting disease associated with the human immunodeficiency virus through the use of monoclonal antibodies directed against anti-self cytotoxic T-lymphocytes or their lytics | |
| RU94045248A (ru) | Способ ингибирования активности вируса иммунодефицита человека (hiv) in vivo | |
| Panzer et al. | Efficacy of rhesus antibodies (anti-Rh 0 (D)) in autoimmune thrombocytopenia: Correlation with response to high dose IgG and the degree of haemolysis | |
| EP0319333B1 (fr) | Procédé pour la prévention de réaction de rejet | |
| Bretscher | An hypothesis to explain why cell‐mediated immunity alone can contain infections by certain intracellular parasites and how immune class regulation of the response against such parasites can be subverted | |
| Emmerich et al. | Dose-response relationship in the treatment of idiopathic thrombocytopenic purpura with intravenous immunoglobulin | |
| Vecchiarelli et al. | Antibody to Cryptococcus neoformans capsular glucuronoxylomannan promotes expression of interleukin‐12Rβ2 subunit on human T cells in vitro through effects mediated by antigen‐presenting cells | |
| Krakauer | Clinical applications of monoclonal antibodies | |
| Cacopardo et al. | HCV and HIV infection among intravenous drug abusers in eastern Sicily | |
| Gardner | Bill puts VA cuts at $50 million for 1995. | |
| Dunn et al. | Simultaneous treatment of concurrent rejection and tissue invasive cytomegalovirus disease without detrimental effects upon patient or allograft survival | |
| WO1994023747A1 (fr) | Medicament contenant des anticorps, utilise dans le traitement de reactions immunes specifiques des lymphocytes t et de leucemies a lymphocytes t | |
| Hogerzeil | Lamprene: First Results of Treatment in the Netherlands in a Group of 6 Leprosy Patients |